Recent progress in understanding the molecular mechanisms of bile formation and cholestasis have led to new insights into the pathogenesis of drug-induced cholestasis. This review summarizes their variable clinical presentations, examines the role of transport proteins in hepatic drug clearance and toxicity, and addresses the increasing importance of genetic determinants, as well as practical aspects of diagnosis and management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089004 | PMC |
| http://dx.doi.org/10.1002/hep.24229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obeticholic acid aggravates liver fibrosis by activating hepatic farnesoid X receptor-induced apoptosis in cholestatic mice.
Chem Biol Interact
December 2024
New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address:
Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) patients. However, it can cause severe drug-induced liver injury (DILI), which may put PBC patients at risk of acute-on-chronic liver failure (ACLF) and even death. Farnesoid X receptor (FXR) is considered as the target of OCA for cholestasis, but there is still a lack of research on whether hepatic and ileal FXR have different effects after OCA treatment.
View Article and Find Full Text PDFPractical guide for the diagnosis and treatment of localized and generalized cutaneous pruritus (chronic itch with no underlying pruritic dermatosis).
J Dermatol
December 2024
Department of Dermatology, National Defense Medical College, Tokorozawa, Japan.
Itch, also known as pruritus, is one of the most prevalent symptoms observed in dermatological practices. Itch frequently arises from primary pruritic dermatoses, although it may also manifest in the absence of a primary pruritic skin rash. The latter itchy condition is referred to as "cutaneous pruritus" in the Japanese guidelines published in 2020.
View Article and Find Full Text PDFDrug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms.
Arch Toxicol
November 2024
Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland.
Article Synopsis
- Drug-induced cholestasis (DIC) is a significant concern in drug development, as it disrupts bile flow and causes toxic buildup of bile acids in the liver, representing a type of drug-induced liver injury (DILI).
- Researchers developed a predictive model using in vitro data from 47 drugs, which distinguished between drugs with and without DILI concerns, achieving a strong predictive performance (p-value of 0.039, PR AUC of 0.91).
- The study highlights the importance of multiple liver processes in bile acid regulation and suggests that using a quantitative model in preclinical stages can improve drug safety and reduce failures in later development stages.
Vanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury.
BMJ Case Rep
November 2024
Essentia Health Fargo Hospital, Fargo, North Dakota, USA.
Temozolomide (TMZ)-levetiracetam (LEV) combination therapy in glioblastoma management is gradually becoming a mainstay treatment given its superior effect compared with TMZ monotherapy. While there have been previous cases of hepatotoxicity, there are no prior reports of vanishing bile duct syndrome (VBDS) associated with TMZ-LEV combination use. This case report details a male in his 50s who had recently completed TMZ and LEV for right frontal lobe glioblastoma.
View Article and Find Full Text PDF[Clinical characteristics of gene variant-associated cholestatic liver disease in adults].
Zhonghua Gan Zang Bing Za Zhi
October 2024
Department of Hepatology, Fifth Medical Center, PLA General Hospital, Beijing100039, China.
Article Synopsis
- The study aimed to examine the clinical symptoms, pathological features, and gene mutations associated with cholestatic liver disease in adults, analyzing eight cases from a hospital from 2010 to 2022.
- Among the eight patients (3 males, 5 females) with a median age of 24, various clinical phenotypes were identified, including cases related to familial intrahepatic cholestasis and pregnancy-related cholestasis, with many exhibiting liver fibrosis and cirrhosis.
- Genetic testing identified 11 mutations, including 8 new ones, with most found to be harmful, and all patients received treatment with Ursodeoxycholic acid.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!